ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 187,65
0,69%
Dow Jones
39 313,19
0,66%
DAX
18 686,60
1,07%
Brent Oil
83,465
-0,11%
Bitcoin
62 070,73
1,44%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Disc Medicine Inc (IRON)

  7. Disc Medicine Inc (IRON) Actualités

IRON

Disc Medicine (IRON)

Disc Medicine Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IRON
DateHeureSourceTitreSymboleSociété
09/05/202414h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IRONDisc Medicine Inc
09/05/202414h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IRONDisc Medicine Inc
09/05/202414h00GlobeNewswire Inc.Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IRONDisc Medicine Inc
01/04/202414h00GlobeNewswire Inc.Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)NASDAQ:IRONDisc Medicine Inc
21/03/202413h00GlobeNewswire Inc.Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:IRONDisc Medicine Inc
06/03/202422h30GlobeNewswire Inc.Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:IRONDisc Medicine Inc
02/03/202401h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IRONDisc Medicine Inc
26/02/202414h30GlobeNewswire Inc.Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial OfficerNASDAQ:IRONDisc Medicine Inc
20/02/202414h30GlobeNewswire Inc.Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney DiseaseNASDAQ:IRONDisc Medicine Inc
15/02/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IRONDisc Medicine Inc
14/02/202400h51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IRONDisc Medicine Inc
09/02/202415h00GlobeNewswire Inc.Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia VeraNASDAQ:IRONDisc Medicine Inc
07/02/202414h00GlobeNewswire Inc.Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating OfficerNASDAQ:IRONDisc Medicine Inc
03/01/202423h00GlobeNewswire Inc.Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:IRONDisc Medicine Inc
20/12/202322h30GlobeNewswire Inc.Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory BoardNASDAQ:IRONDisc Medicine Inc
12/12/202302h30GlobeNewswire Inc.Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:IRONDisc Medicine Inc
11/12/202318h00GlobeNewswire Inc.Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:IRONDisc Medicine Inc
07/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IRONDisc Medicine Inc
05/12/202322h53Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:IRONDisc Medicine Inc
05/12/202322h51Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IRONDisc Medicine Inc
14/11/202322h44GlobeNewswire Inc.Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with BitopertinNASDAQ:IRONDisc Medicine Inc
13/11/202312h46Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:IRONDisc Medicine Inc
09/11/202314h30GlobeNewswire Inc.Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:IRONDisc Medicine Inc
08/11/202322h30GlobeNewswire Inc.Disc Medicine to Participate in Upcoming Investor ConferencesNASDAQ:IRONDisc Medicine Inc
02/11/202314h00GlobeNewswire Inc.Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program UpdatesNASDAQ:IRONDisc Medicine Inc
23/10/202315h15GlobeNewswire Inc.Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne BryceNASDAQ:IRONDisc Medicine Inc
03/10/202314h30GlobeNewswire Inc.Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy VolunteersNASDAQ:IRONDisc Medicine Inc
25/09/202322h56Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IRONDisc Medicine Inc
20/09/202323h18Dow Jones NewsDisc Medicine Polycythemia Vera Treatment MWTX-003 Gets FDA Fast Track DesignationNASDAQ:IRONDisc Medicine Inc
20/09/202322h30GlobeNewswire Inc.Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia VeraNASDAQ:IRONDisc Medicine Inc
 Showing the most relevant articles for your search:NASDAQ:IRON

Dernières Valeurs Consultées

EU
AI
Air Liquide
EU
SGO
Cie de SaintGobain
EU
CS
Axa
EU
LR
Legrand
EU
VK
Vallourec
NASDAQ
AAPL
Apple
EU
RI
Pernod Ricard
NYSE
MCD
McDonalds
USI
USTECH100
US Tech 100
EU
PX1
CAC 40
NYSE
NKE
Nike
EU
EN
Bouygues
EU
RNO
Renault
EU
BEL20
Bel 20
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés